Tilman Brummer

Prof. Dr. Tilman Brummer

orcid

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 February 2016 in Nature Communications
Verified
Journal Article
Open access
WLWaltraut Lehmann
Waltraut Lehmann
DMDirk Mossmann
Dirk Mossmann
JKJulia Kleemann
Julia Kleemann
KMKerstin Mock
Kerstin Mock
CMChris Meisinger
Chris Meisinger
TBThomas Brabletz
Thomas Brabletz
Early dissemination, metastasis and therapy resistance are central hallmarks of aggressive cancer types and the leading cause of cancer-associated deaths. The EMT-inducing transcriptional repressor ZEB1 is a crucial stimulator of these processes, particularly by coupling the activation of cellular motility with stemness and survival properties. ZEB1 expression is associated with aggressive behaviour in many tumour types, but the potent effects cannot be solely explained by its proven function as a transcriptional repressor of epithelial genes. Here we describe a direct interaction of ZEB1 with the Hippo pathway effector YAP, but notably not with its paralogue TAZ. In consequence, ZEB1 switches its function to a transcriptional co-activator of a ‘common ZEB1/YAP target gene set’, thereby linking two pathways with similar cancer promoting effects. This gene set is a predictor of poor survival, therapy resistance and increased metastatic risk in breast cancer, indicating the clinical relevance of our findings.

12 February 2018 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
NMNimitha R Mathew
Nimitha R Mathew
FBFrancis Baumgartner
Francis Baumgartner
LBLukas Braun
Lukas Braun
DODavid O'Sullivan
David O'Sullivan
STSimone Thomas
Simone Thomas
RZRobert Zeiser
Robert Zeiser

12 February 2006 in Nature Immunology
Verified
Journal Article
Closed access
PDF file
KJKate L Jeffrey
Kate L Jeffrey
TBTilman Brummer
Tilman Brummer
MRMichael S Rolph
Michael S Rolph
SLSue M Liu
Sue M Liu
NCNuria A Callejas
Nuria A Callejas
CMCharles R. Mackay
Charles R. Mackay

21 February 2018 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
APAlessandro Prestipino
Alessandro Prestipino
AEAlica J. Emhardt
Alica J. Emhardt
KAKonrad Aumann
Konrad Aumann
DODavid O’sullivan
David O’sullivan
SGSivahari P. Gorantla
Sivahari P. Gorantla
RZRobert Zeiser
Robert Zeiser
Recent evidence has revealed that oncogenic mutations may confer immune escape. A better understanding of how an oncogenic mutation affects immunosuppressive programmed death ligand 1 (PD-L1) expression may help in developing new therapeutic strategies. We show that oncogenic JAK2 (Janus kinase 2) activity caused STAT3 (signal transducer and activator of transcription 3) and STAT5 phosphorylation, which enhanced PD-L1 promoter activity and PD-L1 protein expression in JAK2V617F-mutant cells, whereas blockade of JAK2 reduced PD-L1 expression in myeloid JAK2V617F-mutant cells. PD-L1 expression was higher on primary cells isolated from patients with JAK2V617F–myeloproliferative neoplasms (MPNs) compared to healthy individuals and declined upon JAK2 inhibition. JAK2V617F mutational burden, pSTAT3, and PD-L1 expression were highest in primary MPN patient–derived monocytes, megakaryocytes, and platelets. PD-1 (programmed death receptor 1) inhibition prolonged survival in human MPN xenograft and primary murine MPN models. This effect was dependent on T cells. Mechanistically, PD-L1 surface expression in JAK2V617F-mutant cells affected metabolism and cell cycle progression of T cells. In summary, we report that in MPN, constitutive JAK2/STAT3/STAT5 activation, mainly in monocytes, megakaryocytes, and platelets, caused PD-L1–mediated immune escape by reducing T cell activation, metabolic activity, and cell cycle progression. The susceptibility of JAK2V617F-mutant MPN to PD-1 targeting paves the way for immunomodulatory approaches relying on PD-1 inhibition.

24 May 2011 in Molecular Systems Biology
Verified
Journal Article
Open access
PDF file
RFRaphaela Fritsche
Raphaela Fritsche
FWFranziska Witzel
Franziska Witzel
ASAnja Sieber
Anja Sieber
RHRicarda Herr
Ricarda Herr
NSNadine Schmidt
Nadine Schmidt
NBNils Blüthgen
Nils Blüthgen
EMBO Press is an editorially independent publishing platform for the development of EMBO scientific publications.

14 December 2022 in Journal of Hepatology
Verified
Journal Article
Closed access
GKGajanan Kendre
Gajanan Kendre
KMKarthikeyan Murugesan
Karthikeyan Murugesan
TBTilman Brummer
Tilman Brummer
OSOreste Segatto
Oreste Segatto
ASAnna Saborowski
Anna Saborowski
Arndt VogelArndt Vogel
Arndt Vogel